UCB Makes Another Push To Get Bimzelx Over Finishing Line In US
Potential Blockbuster Resubmitted For Psoriasis
The Belgian group was stunned by an FDA rejection in May for its dual IL-17A and IL-17F inhibitor and although the refiling is complete, UCB may still have to wait six months to get Bimzelx into the all-important US psoriasis market.
